Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940381 · ClinicalTrials.gov registry record · Phase 1
Sirolimus and Cetuximab in Advanced Malignancies
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
NCT00940381: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00940381 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 165 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00940381, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of sirolimus and cetuximab that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Interventions
- DRUG Sirolimus
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940381
The ClinicalTrials.gov registry entry for NCT00940381 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT00940381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00940381 about?
NCT00940381 is a clinical study titled "Sirolimus and Cetuximab in Advanced Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of sirolimus and cetuximab that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT00940381?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2009-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00940381?
The interventions under investigation include: Sirolimus (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00940381?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.